FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110341782> ?p ?o ?g. }

• W2110341782 endingPage "950" @default.
• W2110341782 startingPage "946" @default.
• W2110341782 abstract "Interleukin 1 (IL-1), IL-6, and tumour necrosis factor (TNF) alpha are pleiotropic cytokines produced predominantly by macrophages which have been implicated in the pathogenesis of rheumatoid arthritis (RA). Sulphasalazine has been shown to have disease modifying properties and to inhibit the production of cytokines in vitro. To evaluate the effect of sulphasalazine on cytokine production in vivo, serum cytokine levels were measured in a group of patients with RA entered into a randomised controlled trial. Serum levels of IL-1 alpha, IL-1 beta, IL-6, and TNF alpha were measured at baseline and at two monthly intervals for six months in 17 patients receiving sulphasalazine and in 22 patients treated with placebo. The two groups of patients had a similar age and sex distribution, had had RA for less than a year, had no joint erosions, and had not been treated previously with any other disease modifying drugs. In the 39 patients studied IL-1 alpha was detected (> 0.1 ng/ml) at baseline in 14 patients (median 0.24 ng/ml), IL-1 beta in 25 patients (median 1.0 ng/ml), TNF alpha in 27 patients (median 1.2 ng/ml), and IL-6 in 33 patients (median 0.44 ng/ml). In the group treated with sulphasalazine there was a progressive and significant decline in serum IL-1 alpha, IL-1 beta, and TNF alpha levels over the six month period (median levels at six months were < 0.1, 0.12, and 0.44 ng/ml respectively). Interleukin 6 levels were significantly reduced only at the four month time point (median level of 0.23 ng/ml). These reductions were associated with improvements in clinical and laboratory measures of disease activity. In contrast patients receiving the placebo showed no changes in serum cytokine levels and no improvement in clinical and laboratory indices of disease activity. These results suggest that sulphasalazine may exert its disease modifying effect partly by suppressing cytokine production in vivo." @default.
• W2110341782 created "2016-06-24" @default.
• W2110341782 creator A5005689053 @default.
• W2110341782 creator A5026494458 @default.
• W2110341782 creator A5030544708 @default.
• W2110341782 creator A5030667985 @default.
• W2110341782 creator A5061647624 @default.
• W2110341782 date "1992-08-01" @default.
• W2110341782 modified "2023-10-01" @default.
• W2110341782 title "Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine." @default.
• W2110341782 cites W1597952938 @default.
• W2110341782 cites W1615827574 @default.
• W2110341782 cites W1974357188 @default.
• W2110341782 cites W1983603707 @default.
• W2110341782 cites W1985004174 @default.
• W2110341782 cites W1988834558 @default.
• W2110341782 cites W1996794055 @default.
• W2110341782 cites W1999359514 @default.
• W2110341782 cites W2011934383 @default.
• W2110341782 cites W2014964971 @default.
• W2110341782 cites W2019737992 @default.
• W2110341782 cites W2026080578 @default.
• W2110341782 cites W2035787474 @default.
• W2110341782 cites W2063912082 @default.
• W2110341782 cites W2065344034 @default.
• W2110341782 cites W2090491283 @default.
• W2110341782 cites W2094163077 @default.
• W2110341782 cites W2098015378 @default.
• W2110341782 cites W2112790809 @default.
• W2110341782 cites W2118225161 @default.
• W2110341782 cites W2118766962 @default.
• W2110341782 cites W2126294158 @default.
• W2110341782 cites W2156601212 @default.
• W2110341782 cites W2158034263 @default.
• W2110341782 cites W2384406269 @default.
• W2110341782 cites W2413072592 @default.
• W2110341782 cites W2414817939 @default.
• W2110341782 cites W4245316560 @default.
• W2110341782 cites W4290360381 @default.
• W2110341782 cites W45832520 @default.
• W2110341782 doi "https://doi.org/10.1136/ard.51.8.946" @default.
• W2110341782 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1004800" @default.
• W2110341782 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1358037" @default.
• W2110341782 hasPublicationYear "1992" @default.
• W2110341782 type Work @default.
• W2110341782 sameAs 2110341782 @default.
• W2110341782 citedByCount "80" @default.
• W2110341782 countsByYear W21103417822012 @default.
• W2110341782 countsByYear W21103417822013 @default.
• W2110341782 countsByYear W21103417822014 @default.
• W2110341782 countsByYear W21103417822015 @default.
• W2110341782 countsByYear W21103417822016 @default.
• W2110341782 countsByYear W21103417822017 @default.
• W2110341782 countsByYear W21103417822018 @default.
• W2110341782 countsByYear W21103417822019 @default.
• W2110341782 countsByYear W21103417822021 @default.
• W2110341782 countsByYear W21103417822022 @default.
• W2110341782 countsByYear W21103417822023 @default.
• W2110341782 crossrefType "journal-article" @default.
• W2110341782 hasAuthorship W2110341782A5005689053 @default.
• W2110341782 hasAuthorship W2110341782A5026494458 @default.
• W2110341782 hasAuthorship W2110341782A5030544708 @default.
• W2110341782 hasAuthorship W2110341782A5030667985 @default.
• W2110341782 hasAuthorship W2110341782A5061647624 @default.
• W2110341782 hasBestOaLocation W21103417821 @default.
• W2110341782 hasConcept C126322002 @default.
• W2110341782 hasConcept C142724271 @default.
• W2110341782 hasConcept C17991360 @default.
• W2110341782 hasConcept C203014093 @default.
• W2110341782 hasConcept C204787440 @default.
• W2110341782 hasConcept C27081682 @default.
• W2110341782 hasConcept C2777077863 @default.
• W2110341782 hasConcept C2777575956 @default.
• W2110341782 hasConcept C2778690821 @default.
• W2110341782 hasConcept C2780942790 @default.
• W2110341782 hasConcept C71924100 @default.
• W2110341782 hasConcept C90924648 @default.
• W2110341782 hasConceptScore W2110341782C126322002 @default.
• W2110341782 hasConceptScore W2110341782C142724271 @default.
• W2110341782 hasConceptScore W2110341782C17991360 @default.
• W2110341782 hasConceptScore W2110341782C203014093 @default.
• W2110341782 hasConceptScore W2110341782C204787440 @default.
• W2110341782 hasConceptScore W2110341782C27081682 @default.
• W2110341782 hasConceptScore W2110341782C2777077863 @default.
• W2110341782 hasConceptScore W2110341782C2777575956 @default.
• W2110341782 hasConceptScore W2110341782C2778690821 @default.
• W2110341782 hasConceptScore W2110341782C2780942790 @default.
• W2110341782 hasConceptScore W2110341782C71924100 @default.
• W2110341782 hasConceptScore W2110341782C90924648 @default.
• W2110341782 hasIssue "8" @default.
• W2110341782 hasLocation W21103417821 @default.
• W2110341782 hasLocation W21103417822 @default.
• W2110341782 hasLocation W21103417823 @default.
• W2110341782 hasLocation W21103417824 @default.
• W2110341782 hasLocation W21103417825 @default.
• W2110341782 hasOpenAccess W2110341782 @default.
• W2110341782 hasPrimaryLocation W21103417821 @default.
• W2110341782 hasRelatedWork W1971296504 @default.

• next